US Measles Cases Top 3,100 as Outbreaks Continue in 2026

The United States has recorded more than 3,100 confirmed measles cases so far in 2026, marking the highest annual total in more than three decades and highlighting continued challenges in controlling outbreaks of the highly contagious disease.

According to the US Centers for Disease Control and Prevention (CDC), 3,134 confirmed measles cases had been reported nationwide as of September 4, 2026. The total is already well above the 2,289 cases recorded during the whole of 2025.

The increase has been particularly rapid in recent weeks. CDC data showed 2,777 confirmed cases as of August 20, meaning hundreds of additional infections were reported within a relatively short period. Most cases in 2026 have been associated with outbreaks rather than isolated infections.

Measles was declared eliminated in the United States in 2000, meaning there was no continuous domestic transmission for more than 12 months. However, imported cases can still lead to outbreaks, particularly when the virus reaches communities with lower vaccination coverage.

The CDC has identified declining childhood vaccination rates as one factor contributing to the increased risk. National coverage with the measles, mumps and rubella (MMR) vaccine among kindergarten-aged children has fallen from 95.2% during the 2019–20 school year to 92.4% in 2025–26. Public health officials generally consider coverage above 95% important for maintaining strong community protection against measles.

Measles spreads through the air when an infected person coughs or sneezes and is considered one of the most contagious infectious diseases. Symptoms commonly include fever, cough, runny nose, red eyes and a characteristic rash. While many patients recover without complications, measles can lead to pneumonia, neurological complications and, in rare cases, death.

Vaccination remains the primary preventive measure. Two doses of the MMR vaccine are approximately 97% effective at preventing measles, while one dose is about 93% effective, according to the CDC.

The continuing rise in cases is placing renewed attention on vaccination coverage, outbreak surveillance and the ability of local health departments to rapidly contain transmission.

With several months remaining in 2026, the final case count could rise further. For clinicians, the resurgence also reinforces the importance of considering measles when evaluating patients with compatible symptoms, particularly in areas experiencing active outbreaks or among patients with uncertain vaccination histories. G-Med excels in HCP marketing by blending digital innovation with data-driven insights, creating an effective platform for reaching healthcare professionals, offering various advertising solutions. By using G-Med to engage HCPs, share data reports, and explore innovative channels, marketers can deliver targeted, impactful messages that foster strong connections. G-Med’s approach ensures that each campaign is tailored, scientifically rigorous, and effective, aligning perfectly with the best practices for successful HCP marketing.   

Contact us today to learn more: Contact@g-med.com